Literature DB >> 12942409

Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.

Irja Lutsar1, Sarah Roffey, Peter Troke.   

Abstract

We characterized voriconazole concentrations in the cerebrospinal fluid (CSF) of immunocompetent guinea pigs and patients with invasive fungal infections. In animals, after receipt of oral doses of 4 or 10 mg/kg every 8 h, the mean ratios of CSF to plasma total and free drug concentration were 0.68 and 1.3, respectively. In humans, 1-10 h after receipt of voriconazole, the CSF concentrations ranged from 0.08 to 3.93 microg/mL, and the ratio of CSF to plasma concentration ranged from 0.22 to 1.0 (median, 0.46).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942409     DOI: 10.1086/377131

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  56 in total

Review 1.  Triazole antifungal agents in invasive fungal infections: a comparative review.

Authors:  Cornelia Lass-Flörl
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Human tissue distribution of voriconazole.

Authors:  Stefan Weiler; David Fiegl; Róisín MacFarland; Eva Stienecke; Rosa Bellmann-Weiler; Stefan Dunzendorfer; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 3.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 4.  Treatment principles for Candida and Cryptococcus.

Authors:  Laura C Whitney; Tihana Bicanic
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

5.  Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring.

Authors:  Pier Giorgio Cojutti; Maria Merelli; Lorenzo Allegri; Giuseppe Damante; Matteo Bassetti; Federico Pea
Journal:  Br J Clin Pharmacol       Date:  2018-11-09       Impact factor: 4.335

6.  Reflections on the approach to treatment of a mycologic disaster.

Authors:  David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

7.  Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans.

Authors:  Scott W Mueller; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2011-03-26

8.  Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs.

Authors:  Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain.

Authors:  Woo J Moon; Erica L Scheller; Anupam Suneja; Jacob A Livermore; Anurag N Malani; Varsha Moudgal; Lisa E Kerr; Eric Ferguson; David M Vandenberg
Journal:  Clin Infect Dis       Date:  2014-07-03       Impact factor: 9.079

Review 10.  Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.

Authors:  Rajendra S Kadam; Johannes N Van Den Anker
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.